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Abstract: Monoesters of ginsenoside metabolite M1 at the 3-OH, 4-OH and 6-OH 
positions of the glucose moiety at M1 were synthesized via the reaction of M1 with acyl 
chloride, or acid-N,N'-diisopropylcarbodiimide in the presence of DMAP. Their structures 
were fully characterized by spectral methods. The cytotoxicity of these compounds against 
then MGC80-3 human gastric cancer cell line was also assessed. High inhibitory effects 
were found at a concentration of 100 μg/mL. 
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1. Introduction 
Ginseng (the roots of Panax ginseng C. A. MEYER. Araliaceae) has long been used in eastern Asia 
for their medicinal effects. The beneficial effects of ginseng are attributed to the bioactive components 
presenting in it, and lead to the isolation and identification of the ginsenosides, which are glycosides 
containing an aglycone (protopanaxadiol or protopanaxatriol) with a dammarane skeleton. On the other 
hand, the effect might rise from the metabolites of the glycosides when absorbed by human beings. 
Pharmaceutical studies have shown that upon oral administration of ginseng extract or ginsenosides 
they are deglycosylated by intestinal bacteria into the ginseng saponin metabolite 20-O-β-D-
glucopyranosyl-20(S)-protopanaxadiol (M1, Figure 1), as the main metabolite [1–11]. M1 displays 
anticancer activity through the induction of apoptosis in various types of cancer cells [12–16]. Wang 
proposed that it is M1, instead of Rb1 (a primary glycoside in P. ginseng), that possesses potentially 
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chemopreventive activities in human colorectal cancer [17]. Recently, Kim et al. reported that M1 
could be used to treat inflammatory diseases, such as colitis, by targeting IRAK-1 activation as it 
inhibited the production of proinflammatory cytokines more potently than those of ginsenoside Rb1  
did [18]. Other beneficial metabolic effects, e.g., enhancement of insulin secretion using M1 [19], and 
the anti-diabetic activity of M1 [20], have also been reported. A very recent report revealed that M1 
inhibited the expressions of inducible nitric-oxide synthase, proinflammatory cytokines, monocyte 
chemotactic protein-1, matrix metalloproteinase-3, and matrix metalloproteinase-9 in lipopolysaccharide 
(LPS)-stimulated BV2 microglial cells [21]. It suppresses microglial activation by inhibiting reactive 
oxygen species, and thus, is a promising agent for the treatment of various neurologic disorders. 
Accordingly, it is not surprising that the transformation of ginseng or notoginseng saponins (from the 
herb P. notoginseng, which chemical constituents are similar to the ginsenosides) into M1 and the 
bioactivities of M1 have been the subject of intense focus in the last decade [22–25]. 
Figure 1. The structure and atom numbering of M1. 
 
Hasegawa proposed that the metabolized M1 was esterified with fatty acids in the liver, which 
resulted in longer permanence in the body and exhibits the antitumor activities, and concluded that 
ginsenoside is a pro-drug activated in the body by deglycosylation and esterification [2,11]. Compared 
to the fact that much attention has been devoted to the bioactivities, especially anticancer activity of 
M1 [15–17], there is scant synthetic work related to M1 in the literature [26,27]. Recently, we 
synthesized the monoesters of M1 via introduction of acyl groups onto the 6'-OH of the glucose moiety 
in M1 and found the esterified products exhibited cytotoxicity against several human cancer cell lines 
(breast cancer MCF-7, skin melanoma SK-MEL-2 and human ovarian carcinoma B16) [28]. 
Even though it is reported that only the fatty acid ester substituent was connected to the C-6' 
position [10], there is no experimental evidence to prove it. On the other hand, it is imaginable that 
there may be several possible esterified products due to the existence of multiple hydroxyl groups in 
M1, each being possibly esterified. These isomeric esters may display different bioactivities. A 
systemic investigation of the anti-tumor activity should be important for understanding the metabolite 
products and the possible discovery of more active anti-tumor compounds. Meanwhile, the existence 
of six hydroxyls in M1 makes the esterification products very complex, even for the monoacylation 
products, and makes the synthesis and separation challenging. There are few reports about chemical Molecules 2013, 18 3691 
 
 
esterification of M1, even about directed and selective esterification of glycosides [29]. We tried to 
synthesize the M1 esters by introducing acyl groups onto one of the OH’s in M1. Herein, we wish to 
report that the the 3'-OH, or 4'-OH or 6'-OH of the glucose moiety in M1 can be monoesterified, and 
three different kinds of monoesters of M1 could be thus obtained (Figure 2). In addition, some of their 
antitumor activities are also reported. 
Figure 2. The structures of M1 esters 2–7. 
 
2. Results and Discussion 
2.1. Synthesis 
First, some new esters were synthesized from ginsenoside M1 and carboxylic acids, in the presence 
of promoting reagents. Due to presence of multiple hydroxyl groups in M1, it is a great challenge to 
carry out the esterification selectively, even to obtain a mixture of monoesterified products. 
Introduction of a lauroyl (dodecanoyl) to M1 was performed using the acid-N,N'-diisopropylcarbodiimide 
(DIC) or the acyl chloride as the acylation reagents. Multiple-spots were found in TLC monitoring. 
Three monoesters of M1 were isolated, and they are assigned as the esters bearing an acyloxy group at 
the C-3, C-4, C-6 positions in the glucose moiety of M1, respectively (see Section 2.2). Among the 
three monoesters, the C-6 ester is the most polar one. TLC spots corresponding to the three monoesters 
were found in all cases. Besides the monoesters, there are also less polar products formed, which might 
be di- or multi-esterified products of M1, but the attempts to separate them by column chromatography 
were unsuccessful. As shown in Table 1, a 54% overall yield of the monoesters was obtained using 
100 mol% of the acyl chloride as the acylating agent, Et3N as the solvent and base and DMAP as the 
catalyst. In this way, the reaction is fast and the yield relatively high. Even though 3-[N-decyl-N-(4-
pyridyl)amino]propionic acid (DPAP) has been reported to be a catalyst favoring the selective 
introduction of acyl group to the 6'-OH of the glucose [30], it was not successful for the reaction of M1 
with dodecanoic acid (entry 4). Molecules 2013, 18 3692 
 
 
Table 1. The optimization of reaction conditions. 
Entry Acylating  reagent  Cat. 
M1: Acylating reagent: 
Cat. molar ratio 
Time (h) 
Yield 2C 
(%) 
1 C11H23CO2H-DIC DMAP  1:1:0.5  6  12.5 
2 C11H23CO2H-DIC DMAP  0.5:1:0.3  6  4.6 
3 C11H23CO2H-DIC DMAP  1:2:1  9  5.1 
4 C11H23CO2H-DIC DPAP  1:1:0.5  6  8.7 
5 C11H23COCl DMAP  1:1:0.5  0.5  54.1 
Dichloromethane as the solvent, RT. 
With the optimal reaction conditions in hand, reactions of M1 with other carboxylic acid chlorides 
were carried out, and the results are listed in Table 2. Yields in the 41–54% range were obtained for 
the synthesis of esters of aromatic acid and aliphatic acids. 
Table 2. Synthesis of the monoesters of M1 
a. 
Entry  RCOCl  Time (h)  Prod.  Yield (%) 
1 C11H23COCl 0.6  2C  48 
b 
2 C9H19COCl 0.5  3C  43 
b 
3 C7H15COCl 0.5  4C  48 
b 
4 C5H11COCl 0.5  5C  41 
b 
5  t-C4H9COCl 2.0  6C  48 
b 
6 C6H5COCl 0.5  7C  54 
c 
a Molar ratio of M1/RCOCl/DMAP = 1:1:0.02; 
b isolated yield unless otherwise noted; 
c the yield by HPLC. 
2.2. Structure Characterization of the New Monoesters 2A and 2B 
Previously, we reported the C-6' ester of M1 [28]. Since no characterization data could be found for 
the two new M1 monoesters, we recorded the MS, IR and NMR spectral data, and the structures of the 
products were deduced from these data. The monoesters are coded as 2A, 2B, and 2C according to the 
relative polarity in TLC from the weakest to the strongest. 
The strong IR absorptions for 2A, 2B and 2C at 1730, 1743, 1730 cm
−1, respectively, clearly indicated 
the presence of ester groups in these compounds, along with the absorptions at 3369–3389 cm
−1 due to 
the existence of hydroxy group(s). In high-resolution positive-mode FAB-MS (m/z), major signals at 
827.6005, 827.5996, 827.5687 for 2A, 2B and 2C, respectively, are in agreement with the composition 
[C48H84O9Na]
+, therefore, 2A,  2B and 2C all have the same composition of C48H84O9, which 
corresponds to the monolauroyl ester of M1. 
The connection positions of the acyl to M1 were deduced from NMR data. First, the 
1H-NMR 
signals in the range of δ = 5.2–3.0 ppm for 2A, 2B and 2C were assigned from the 
1H-
1H COSY 
(Figures 3–5), starting from the dual proton peak attached to C-1'. The combination of 
1H-
1H COSY, 
DEPT, and HSQC leads to the assignment of most of the signals. Then, an unambiguous structure 
assignment of 2A, 2B and 2C was achieved with resort to the HMBC data (Figure 6), where the 
correlations between the 
13C signal of the carbonyl and proton attached to the glucose moiety were 
observed. Thus, 2A, 2B and 2C were confirmed as monoesters of M1 which contain a lauroyloxy 
group at the C-3', C-4', and C-6' positions, respectively. Even though no much difference is seen in the Molecules 2013, 18 3693 
 
 
NMR for the aglycone moiety in M1 and its esters, the signals corresponding to the glycosyl are very 
different. The 
1H-NMR and 
13C-NMR data for the glucose moiety in M1, 2A, 2B and 2C are listed in 
Tables 3 and 4, respectively. The introduction of an acyl group to the hydroxy group in the glucose 
moiety results in a remarkable downfield shift of the proton signal attached to the carbon which 
connects an acyloxy group. In 2A, the signal for the proton at C-3' appeared at δ 4.91 ppm, which is ∆δ 
1.43 ppm downfield when compared to that in M1. The H-4' signal in 2B changes to δ 4.87 ppm, 
whereas the corresponding H-4' signal in M1 is at δ 3.59 ppm. For 2C, there is a ∆δ 0.48 ppm 
downfield shift for H-6'. In the 
13C-NMR spectra of 2A and 2C, there are 1.33–1.84 ppm changes to  
high-field for the carbons connecting an acyl group. In 2B, the C-4' signal is abnormally shifted to 
downfield by 0.45 ppm. In 2A, 2B and 2C, the NMR signals of the carbons proximal to the carbon 
attached to an acyloxyl group appear remarkably downfield, in the range of δ 1.29–2.49 ppm. 
Therefore, it would be easy to judge the connecting mode of a monoester of M1. Trends of the change 
of chemical shifts in both 
1H-NMR and 
13C-NMR, except that of the C-4' signal in 2B, are in 
agreement with the literature data [31,32]. 
2.3. Cytotoxicity of the Synthesized Monoesters 
The monoesters of M1 were subjected to bioassays against the human gastric cancer cell line 
MGC80-3, and the results are shown in Table 5. All the esters derived from M1 show strong cytotoxic 
activities against MGC80-3 cells at 24 h and 48 h at a concentration of 100 μg/mL. The cytotoxicity is 
much higher than in the control experiment using 5-FU at 10 μg/mL. Even though the mass 
concentrations of the M1 esters are one order higher than that of 5-FU, their molar concentrations are 
very close each other. M1 esters with a longer chain acyl displayed higher activities than those with 
shorter chains against the cells. The M1 ester of benzoic acid is also highly effective at inhibiting the 
cells. Remarkably, 2B, 4'-C11CO2-M1, at 10 μg/mL can inhibit 43% of the cells in 24 h. 
Figure 3. 
1H-
1H COSY spectrum of 2A. 
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Figure 4. 
1H-
1H COSY spectrum of 2B. 
 
Figure 5. 
1H-
1H COSY spectrum of 2C (part). 
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Figure 6. Selected key HMBC correlations of 2A (H→C). 
 
Table 3. 
1H-NMR data of the glycosyls in M1, 2A, 2B and 2C in CDCl3 (δ in ppm,  
J in Hz, recorded at 500 MHz). 
Position  δM1  δ2A (C-3' ester)  δ2B (C-4' ester) δ2C (C-6' ester) 
1'  4.57 (d, 7.3)  4.62 (d, 7.8)  4.56 (d, 7.7)  4.49 (d, 7.7) 
2'  3.21 (dd, 8.0)  3.46 (t, 8.9)  3.41 (t, 8.4)  3.31 (m) 
3'  3.46 (m)  4.91 (t, 9.3)  3.69 (t, 9.4)  3.42 (m) 
4'  3.61 (m)  3.65 (t, 9.1)  4.87 (t, 9.6)  3.62 (m) 
5'  3.33 (m)  3.35 (m)  3.38 (m)  3.35 (m) 
6'  3.77 (dd, 7.5, 11.2) 
3.87 (dd, 3.3, 11.9) 
3.77 (dd, 4.7, 11.9)
3.65 (m)  
3.56 (m) 
4.24 (dd, 11.0, 5.4) 
4.37 (d, 11.2) 
Table 4. 
13C-NMR data of the glycosyls in M1, 2A, 2B and 2C in CDCl3 (δ in ppm,  
J in Hz, recorded at 125 MHz). 
Position  δM1  δ2A  δ2A-δM1 δ2B  δ2B-δM1  δ2C  δ2C-δM1 
1' 98.0  97.3 −0.7 96.8 −1.2 97.0 −1.0 
2' 73.7  72.0 −1.7 74.3 0.6  73.4 −0.3 
3' 77.0  78.3 1.3  74.7 −2.3 76.8 −0.2 
4' 70.1  69.6 −0.5 70.5 −0.4 70.1 0.0 
5' 76.0  75.6 −0.4 74.1 −1.9 73.6 −2.4 
6' 61.5  62.4 0.9  61.7 0.2  63.2 1.7 
Table 5. Cytotoxic efffects of monoesters of M1 on MGC80-3 
a. 
Samples  Inhibitory in 24 h (%) (%) Inhibitory in 48 h (%)  
2B  45.9   98.1  
3C  97.7   78.9  
4C  53.1   54.6  
5C  32.4   86.4  
6C  42.4   57.7  
7C  82.0   90.4  
5-FU 
b  14.8   37.0  
a 100 μg/mL unless noted; 
b 10 μg/mL. Molecules 2013, 18 3696 
 
 
3. Experimental 
3.1. General 
All chemicals were purchased from Alfa Aesar Co., Ltd. (Tianjin, China) except M1, which was 
provided by Dalian Polytechnic University. NMR spectra were recorded on a Bruker DRX500 
spectrometer in CDCl3 using TMS as an internal standard. IR spectra were recorded on a Nicolet 550 
spectrometer. HRMS were recorded on a Micromass UPLC/Q-TOF Micro spectrometer. 
3.2. Synthesis of Monoesters of M1 
To a solution of M1 (100 mg) in CH2Cl2 (5.0 mL) were added DMAP (1.4 mg), C11H23COOH (67 mg) 
and N,N'-diisopropylcarbodiimide in sequence at 0 °C. The mixture was stirred at that temperature 
until TLC monitoring indicated most of M1 was consumed. After quenching the reaction by adding 
aqueous Na2CO3, extraction, drying and evaporation of the solvent, the residue was purified by column 
chromatography on silica gel. Elution with EA/PE (1:4 to 3:7 to 1:1) gave 2A, 2B and 2C. 
3β,12β,20(S)-Trihydroxy-dammar-24-ene 20-O-β-D-glucopyranoside (M1). 
1H-NMR (500 MHz, CDCl3) δ 
5.07 (t, J = 6.4 Hz, 1H, H-24), 4.57 (d, J = 7.3 Hz, 1H, H-1'), 3.77 (dd, J = 19.0, 11.3 Hz, 2H, H-6'), 3.61 
(m, 1H, H-4'), 3.58 (s, br, 2H), 3.53 (m, 1H, H-12), 3.46 (m, 1H, H-3'), 3.33 (m, 1H, H-5'), 3.23 (m, 
1H, H-3), 3.21 (d, J = 8.0 Hz, 1H, H-2'), 2.18 (dd, J = 17.6, 8.8 Hz, 1H, H-17), 2.03 (m, 2H,   
H-23), 1.87 (m, 2H, H-16), 1.85–1.71 (m, 5H), 1.69 (s, 3H, H-26), 1.64 (m, 2H, H-22), 1.60 (s, 3H,  
H-27), 1.52 (m, 2H, H-15), 1.54–1.31 (m, 10H), 1.30 (s, 3H, H-21), 1.22 (m, 1H, Ha-7), 0.97 (s, 6H, 
H-19, H-28), 0.90 (s, 3H, H-30), 0.87 (s, 3H, H-18), 0.77 (s, 3H, H-29), 0.72 (d, J = 10.1 Hz, 1H, H-5); 
13C-NMR (125 MHz, CDCl3) δ 131.7 (C-25), 124.7 (C-24), 98.0 (C-1'), 84.1 (C-20), 79.0 (C-3), 77.0 
(C-3'), 76.0 (C-5'), 73.7 (C-2'), 70.1 (C-4'), 69.2 (C-12), 61.5 (C-6'), 56.1 (C-5), 52.2 (C-17), 51.7 (C-14), 
50.1 (C-9), 48.4 (C-13), 39.9 (C-8), 39.2 (C-4), 39.1 (C-1), 37.2 (C-10), 35.4 (C-22), 34.9 (C-7), 30.9 
(C-11), 30.2 (C-15), 28.2 (C-28), 27.5 (C-2), 26.7 (C-16), 25.9 (C-26), 23.2 (C-23), 22.5 (C-21), 18.4 
(C-6), 18.0 (C-27), 17.3 (C-30), 16.3 (C-29), 15.9 (C-18), 15.6 (C-19). 
3β,12β,20(S)-Trihydroxy-dammar-24-ene 20-O-β-D-glucopyranosyl 3'-lauroyl ester ( 2A). White 
powder. mp: 92–93 °C. [α]
25 
D  + 25° (c 1.02, CH2Cl2). IR (KBr): 3362, 2966, 2932, 2851, 1730, 1629, 
1454, 1387 cm
−1. HRMS (m/z): 827.6005 [M+Na]
+ (calcd. for C48H84O9Na: 827.6013). 
1H-NMR 
(CDCl3, 500 MHz)  5.10 (t, J = 6.6 Hz, 1H, H-24), 4.91 (t, J = 9.3 Hz, 1H, H-3'), 4.62 (t, J = 7.8 Hz, 
1H, H-1'), 3.87 (dd, J = 3.3 Hz, 1H, Ha-6'), 3.77 (dd, J = 4.7, 11.9 Hz, 1H, Hb-6'), 3.65 (t, J = 9.1 Hz, 
1H, H-4'), 3.58 (dt, J = 5.3, 10.3 Hz, 1H, H-12), 3.46 (t, J = 8.9 Hz, 1H, H-2'), 3.35 (m, 1H, H-5'), 3.19 
(dd, J = 4.6 Hz, 1H, H-3), 3.03 (s, br, 1H), 2.40 (t, J = 7.5 Hz, 2H, H-2''), 2.18 (m, 1H, H-17), 2.07 (m, 
1H, Ha-23), 2.00 (m, 1H, Hb-23), 1.89 (m, 1H, Ha-16), 1.85–1.71 (m, 7H), 1.69 (s, 3H, H-26), 1.66–1.62 
(m, 4H), 1.61 (s, 3H, H-27), 1.56–1.38 (m, 6H), 1.34 (s, 3H, H-21), 1.31–1.19 (m, 21H), 0.98 (s, 3H, 
H-28), 0.97 (s, 3H, H-19), 0.97 (m, 1H, Hb-1),0.89 (s, 3H, H-30), 0.88 (t, J = 7.3 Hz, 3H, H-12''), 0.87 
(s, 3H, H-18), 0.78 (s, 3H, H-29), 0.71 (m, 1H, H-5); 
13C-NMR (125 MHz, CDCl3) δ 175.6 (C-1''), 
131.8 (C-25), 124.3 (C-24), 97.3 (C-1'), 84.6 (C-20), 78.9 (C-3), 78.3 (C-3'), 75.6 (C-5'), 72.0 (C-2'), 
70.6 (C-12), 69.6 (C-4'), 62.4 (C-6'), 55.9 (C-5), 51.7 (C-17), 51.5 (C-14), 49.8 (C-9), 48.1 (C-13), Molecules 2013, 18 3697 
 
 
39.8 (C-8), 39.0 (C-4), 38.9 (C-1), 37.1 (C-10), 35.4 (C-22), 34.8 (C-7), 34.4 (C-2''), 31.9 (C-10''), 30.6 
(C-11), 30.4 (C-15), 29.7 (C-7''), 29.6 (C-6''), 29.5 (C-8''), 29.4 (C-5''), 29.3 (C-9''), 29.1 (C-4''), 28.1 
(C-28), 27.4 (C-2), 26.6 (C-16), 25.7 (C-26), 25.3 (C-3''), 24.9 (C-23), 22.7 (C-11''), 22.4 (C-21), 18.3 
(C-6), 17.8 (C-27), 17.0 (C-30), 16.1 (C-29), 15.8 (C-18), 15.4 (C-19), 14.1 (C-12''). 
3β,12β,20(S)-Trihydroxy-dammar-24-ene 20-O-β-D-glucopyranosyl 4'-lauroyl ester (2B). Colorless oil. 
[α]
25 
D  + 17° (c 2.00, CH2Cl2). IR (KBr): 3389, 2966, 2919, 2851, 1743, 1663, 1622, 1461, 1387, 1622 cm
−1. 
HRMS (m/z): 827.5996 [M+Na]
+ (calcd. for C48H84O9Na: 827.6013). 
1H-NMR (500 MHz, CDCl3) δ 
5.10 (s, br, 1H), 5.09 (t, J = 6.6 Hz, 1H, H-24), 4.87 (t, J = 9.6 Hz, 1H, H-4'), 4.56 (d, J = 7.7 Hz, 1H, 
H-1'), 4.33 (s, br, 2H), 3.69 (t, J = 9.6 Hz, 1H, H-3'), 3.65 (m, 1H, Ha-6'), 3.59 (m, 1H, H-12), 3.56  
(m, 1H, Hb-6'), 3.41 (t, J = 8.4 Hz, 1H, H-2'), 3.38 (m, 1H, H-5'), 3.20 (dd, J = 11.2, 4.6 Hz, 1H, H-3), 
2.86 (s, br, 1H), 2.37 (m, 2H, H-2''), 2.21 (m, 2H, H-23), 1.93–1.73 (m, 5H), 1.69 (s, 3H, H-26), 1.64 
(m, 2H, H-22), 1.61 (s, 3H, H-27), 1.58–1.36 (m, 6H), 1.34 (s, 3H, H-21), 1.33–1.28 (m, 6H), 1.27–1.24 
(m, 10H), 1.19–1.02 (m, 3H), 0.99 (s, 3H, H-28), 0.98 (s, 3H, H-19), 0.90 (s, 3H, H-30), 0.88 (s, 3H, 
H-18), 0.87 (m, 3H, H-12''), 0.87–0.82 (m, 6H), 0.78 (s, 3H, H-29), 0.72 (d, J = 11.4 Hz, 1H, H-5); 
13C-NMR (125 MHz, CDCl3) δ 174.0 (C-1''), 131.9 (C-25), 124.3 (C-24), 96.8 (C-1'), 84.4 (C-20), 
78.9 (C-3), 74.7 (C-3'), 74.3 (C-2'), 74.1 (C-5'), 70.7 (C-12), 70.5 (C-4'), 61.7 (C-6'), 55.9 (C-5), 51.7 
(C-17), 51.5 (C-14), 49.9 (C-9), 48.1 (C-13), 39.8 (C-8), 39.0 (C-4), 38.9 (C-1), 37.1 (C-10), 35.5  
(C-22), 34.8 (C-7), 34.4 (C-2''), 31.9 (C-10''), 30.7 (C-11), 30.5 (C-15), 29.7 (C-7''), 29.6 (C-6''), 29.5 
(C-8''), 29.3 (C-5''), 29.2 (C-9''), 29.1 (C-4''), 28.1 (C-28), 27.4 (C-2), 26.7 (C-16), 25.7 (C-26), 25.3 
(C-3''), 24.9 (C-23), 22.7 (C-11''), 22.4 (C-21), 18.3 (C-6), 17.8 (C-27), 17.0 (C-30), 16.2 (C-29), 15.8 
(C-18), 15.4 (C-19), 14.1 (C-12''). 
3β,12β,20(S)-Trihydroxy-dammar-24-ene 20-O-β-D-glucopyranosyl 6'-lauroyl ester (2C). Colorless oil. 
[α]
25 
D  + 16° (c 1.01, CH2Cl2). IR (KBr): 3389, 2959, 2925, 2851, 1730, 1622, 1461, 1407 cm
−1. HRMS 
(m/z): 827.5687 [M + Na]
+ (calcd. for C48H84O9Na: 827.6013). 
1H-NMR (500 MHz, CDCl3) δ 5.24 (s, 
br, 1H), 5.10 (t, J = 6.6 Hz, 1H, H-24), 4.49 (d, J = 7.7 Hz, 1H, H-1'), 4.30 (s, br, 2H), 4.37 (d, J = 11.2 Hz, 
1H, Ha-6'), 4.24 (dd, J = 11.0, 5.4 Hz, 1H, Hb-6'), 3.67 (dd, J = 16.2, 6.9 Hz, 1H, H-12), 3.62 (m, 1H, H-4'), 
3.42 (m, 1H, H-3'), 3.35 (m, 1H, H-5'), 3.31 (m, 1H, H-2'), 3.28 (s, br, 1H), 3.20 (dd, J = 11.3, 4.7 Hz, 
1H, H-3), 2.31 (t, J = 7.6 Hz, 2H, H-2''), 2.19 (m, 2H, H-23), 1.95 (m, 1H, H-13), 1.91–1.73 (m, 8H), 
1.68 (s, 3H, H-26), 1.63 (m, 2H, H-22), 1.60 (s, 3H, H-27), 1.58–1.37 (m, 8H), 1.34 (s, 3H, H-21), 
1.31–1.21 (m, 18H), 1.02 (m, 1H, Ha-15), 0.98 (s, 3H, H-28), 0.97 (s, 3H, H-19), 0.90 (s, 3H, H-30), 
0.88 (s, 3H, H-18), 0.87 (t, J = 7.2 Hz, 3H, H-12''), 0.78 (s, 3H, H-29), 0.72 (d, J = 11.3 Hz, 1H, H-5); 
13C-NMR (125 MHz, CDCl3) δ 174.1 (C-1''), 131.6 (C-25), 124.6 (C-24), 97.0 (C-1'), 84.4 (C-20), 78.9 (C-3), 
76.8 (C-3'), 73.6 (C-5'), 73.4 (C-2'), 70.7 (C-12), 70.1 (C-4'), 63.2 (C-6'), 55.9 (C-5), 51.8 (C-17), 51.4  
(C-14), 49.8 (C-9), 47.9 (C-13), 39.8 (C-8), 39.0 (C-4), 38.9 (C-1), 37.1 (C-10), 35.5 (C-22), 34.8 (C-7), 
34.2 (C-2''), 31.9 (C-10''), 30.6 (C-11), 30.3 (C-15), 29.7 (C-7''), 29.6 (C-6''), 29.5 (C-8''), 29.4 (C-5''), 29.3 
(C-9''), 29.2 (C-4''), 28.1 (C-28), 27.4 (C-2), 26.8 (C-16), 25.7 (C-26), 25.3 (C-3''), 24.9 (C-23), 22.7 (C-11''), 
22.1 (C-21), 18.3 (C-6), 17.7 (C-27), 17.0 (C-30), 16.2 (C-29), 15.8 (C-18), 15.4 (C-19), 14.1 (C-12''). 
3β,12β,20(S)-Trihydroxy-dammar-24-ene 20-O-β-D-glucopyranosyl 6'-decanoyl ester (3C). Colorless 
oil. HRMS (m/z): 799.5667 [M + Na]
+ (calcd. for C46H80O9Na: 799.5700). 
1H-NMR (500 MHz, Molecules 2013, 18 3698 
 
 
CDCl3) δ 5.24 (s, br, 1H), 5.11 (t, J = 7.0 Hz, 1H, H-24), 4.58 (s, br, 1H), 4.49 (d, J = 7.7 Hz, 1H,  
H-1'), 4.36 (d, J = 11.4 Hz, 1H, Ha-6'), 4.28 (dd, J = 11.3, 4.6 Hz, 1H, Hb-6'), 3.62 (m, 1H, H-12), 3.59 
(m, 1H, H-4'), 3.42 (d, J = 5.5 Hz, 1H, H-3'), 3.34 (m, 1H, H-5'), 3.26 (m, 1H, H-2'), 3.20 (dd, J = 11.4, 
4.8 Hz, 1H, H-3), 3.08 (s, br, 1H), 2.31 (t, J = 7.5 Hz, 2H, H-2''), 2.22 (m, 1H, H-17), 2.10 (m, 1H,  
Ha-23), 1.99 (m, 1H, H-13), 1.89 (m, 1H, Ha-16), 1.78 (m, 2H, H-2), 1.69 (s, 3H, H-26), 1.67–1.62 
(m, 6H), 1.60 (s, 3H, H-27), 1.58–1.37 (m, 8H), 1.35 (s, 3H, H-21), 1.31–1.26 (m, 16H), 1.05 (m, 1H, 
Ha-15), 0.98 (s, 3H, H-28), 0.97 (s, 3H, H-19), 0.90 (s, 3H, H-30), 0.88 (s, 3H, H-18), 0.87 (t, J = 7.0 Hz, 
3H, H-10''), 0.78 (s, 3H, H-29), 0.72 (d, J = 11.3 Hz, 1H, H-5); 
13C-NMR (125 MHz, CDCl3) δ 174.2 
(C-1''), 131.7 (C-25), 124.7 (C-24), 97.1 (C-1'), 84.5 (C-20), 79.0 (C-3), 76.8 (C-3'), 73.7 (C-5'), 73.6 
(C-2'), 70.8 (C-12), 70.2 (C-4'), 63.5 (C-6'), 56.0 (C-5), 51.9 (C-17), 51.5 (C-14), 50.0 (C-9), 48.1 (C-13), 
40.0 (C-8), 39.1 (C-4), 38.8 (C-1), 37.3 (C-10), 35.6 (C-22), 34.9 (C-7), 34.4 (C-2''), 32.0 (C-8''), 30.8 
(C-11), 30.7 (C-15), 29.6 (C-6''), 29.4 (C-5'', C-7''), 29.3 (C-4''), 28.2 (C-28), 27.6 (C-2), 26.9 (C-16), 
25.8 (C-26), 25.0 (C-3''), 24.9 (C-23), 22.8 (C-9''), 22.2 (C-21), 18.4 (C-6), 17.8 (C-27), 17.1 (C-30), 
16.3 (C-29), 15.9 (C-18), 15.5 (C-19), 14.2 (C-10''). 
3β,12β,20(S)-Trihydroxy-dammar-24-ene 20-O-β-D-glucopyranosyl 6'-octanoyl ester (4C). Colorless 
oil. HRMS (m/z): 771.5388 [M + Na]
+ (calcd. for C44H76O9Na: 771.5387). 
1H-NMR (500 MHz, CDCl3) 
δ 5.28 (s, br, 1H), 5.10 (t, J = 7.0 Hz, 1H, H-24), 4.69 (s, br, 1H), 4.50 (d, J = 7.7 Hz, 1H, H-1'), 4.39 
(d, J = 10.5 Hz, 1H, Ha-6'), 4.22 (dd, J = 11.8, 5.8 Hz, 1H, Hb-6'), 3.72 (s, br, 1H), 3.59 (m, 1H, H-4'), 
3.44 (m, 1H, H-3'), 3.36 (m, 1H, H-5'), 3.33 (t, J = 8.3 Hz, 1H, H-2'), 3.20 (dd, J = 11.1, 4.7 Hz, 1H, 
H-3), 2.30 (t, J = 7.6 Hz, 2H, H-2''), 2.14 (m, 1H, Ha-23), 2.08 (m, 1H, Ha-22), 2.02–1.70 (m, 8H), 
1.68 (s, 3H, H-26), 1.66–1.62 (m, 4H), 1.60 (s, 3H, H-27), 1.57–1.43 (m, 4H), 1.40 (m, 2H, H-6), 1.36 
(m, 1H, Ha-11), 1.34 (s, 3H, H-21), 1.32–1.24 (m, 12H), 1.02 (m, 1H, Ha-15), 0.98 (s, 6H, H-19,  
H-28), 0.89 (s, 3H, H-30), 0.87 (s, 3H, H-18), 0.85 (t, J = 6.8 Hz, 3H, H-8''), 0.78 (s, 3H, H-29), 0.72 
(d, J = 11.2 Hz, 1H, H-5); 
13C-NMR (125 MHz, CDCl3) δ 174.1 (C-1''), 131.5 (C-25), 124.8 (C-24), 
96.9 (C-1'), 84.3 (C-20), 79.0 (C-3), 77.1 (C-3'), 73.7 (C-5'), 73.5 (C-2'), 70.7 (C-12), 70.3 (C-4'), 63.6 
(C-6'), 56.1 (C-5), 51.8 (C-17), 51.5 (C-14), 50.0 (C-9), 48.1 (C-13), 39.9 (C-8), 39.0 (C-1, C-4), 37.2 
(C-10), 35.6 (C-22), 34.9 (C-7), 34.3 (C-2''), 31.8 (C-6''), 30.8 (C-11), 30.5 (C-15), 29.3 (C-4''), 29.1 
(C-5''), 28.2 (C-28), 27.5 (C-2), 26.8 (C-16), 25.8 (C-26), 25.1 (C-3''), 24.6 (C-23), 22.7 (C-7''), 22.3 
(C-21), 18.4 (C-6), 17.8 (C-27), 17.1 (C-30), 16.3 (C-29), 15.9 (C-18), 15.5 (C-19), 14.2 (C-8''). 
3β,12β,20(S)-Trihydroxy-dammar-24-ene 20-O-β-D-glucopyranosyl 6'-hexyl ester (5C). Colorless oil. 
HRMS (m/z): 743.5054 [M + Na]
+ (calcd. for C42H72O9Na: 743.5074). 
1H-NMR (500 MHz, CDCl3) δ 
5.21 (s, br, 1H), 5.10 (t, J = 7.0 Hz, 1H, H-24), 4.53 (s, br, 1H), 4.52 (d, J = 7.7 Hz, 1H, H-1'), 4.38 (m, 
1H, Ha-6'), 4.21 (dd, J = 11.8, 6.0 Hz, 1H, Hb-6'), 3.79 (s, br, 1H), 3.70 (m, 1H, H-12), 3.64 (m, 1H, 
H-4'), 3.45 (m, 1H, H-3'), 3.33 (t, J = 8.4 Hz, 1H, H-5'), 3.29 (m, 1H, H-2'), 3.20 (dd, J = 11.2, 4.8 Hz, 
1H, H-3), 2.30 (t, J = 7.6 Hz, 2H, H-2''), 2.24–2.10 (m, 2H), 2.04–1.70 (m, 6H), 1.68 (s, 3H, H-26), 
1.65–1.61 (m, 3H), 1.60 (s, 3H, H-27), 1.53–1.45 (m, 6H), 1.36 (m, 1H, Ha-11), 1.34 (s, 3H, H-21),  
1.32–1.20 (m, 8H), 1.05 (m, 1H, Ha-15), 0.98 (s, 6H, H-19, H-28), 0.92–0.88 (m, 2H), 0.89 (s, 3H,  
H-30), 0.88 (t, J = 7.0 Hz, 3H, H-6''), 0.87 (s, 3H, H-18), 0.78 (s, 3H, H-29), 0.72 (d, J = 11.3 Hz, 1H, 
H-5); 
13C-NMR (125 MHz, CDCl3) δ 174.0 (C-1''), 131.5 (C-25), 124.8 (C-24), 96.9 (C-1'), 84.2  
(C-20), 78.9 (C-3), 77.1 (C-3'), 73.6 (C-5'), 73.5 (C-2'), 70.6 (C-12), 70.4 (C-4'), 63.7 (C-6'), 56.0  Molecules 2013, 18 3699 
 
 
(C-5), 51.7 (C-17), 51.5 (C-14), 49.9 (C-9), 48.1 (C-13), 39.9 (C-8), 39.1 (C-1), 39.0 (C-4), 37.2  
(C-10), 35.6 (C-22), 34.9 (C-7), 34.3 (C-2''), 31.4 (C-3'', C-4''), 30.7 (C-11), 30.5 (C-15), 28.2 (C-28), 
27.5 (C-2), 26.7 (C-16), 25.8 (C-26), 24.7 (C-23), 22.4 (C-5''), 22.2 (C-21), 18.4 (C-6), 17.8 (C-27), 
17.1 (C-30), 16.2 (C-29), 15.9 (C-18), 15.5 (C-19), 14.1 (C-6''). 
3β,12β,20(S)-Trihydroxy-dammar-24-ene 20-O-β-D-glucopyranosyl 6'-isobutyryl ester (6C). Colorless 
oil. HRMS (m/z): 729.4910 [M + Na]
+ (calcd. for C41H70O9Na: 729.4918). 
1H-NMR (500 MHz, 
CDCl3) δ 5.25 (s, br, 1H), 5.10 (t, J = 7.0 Hz, 1H, H-24), 4.61 (s, br, 1H), 4.52 (d, J = 7.6 Hz, 1H,  
H-1'), 4.43 (dd, J = 11.7, 1.5 Hz, 1H, Ha-6'), 4.14 (dd, J = 11.9, 6.6 Hz, 1H, Hb-6'), 3.73 (s, br, 1H), 
3.66 (m, 1H, H-12), 3.60 (m, 1H, H-4'), 3.45 (m, 1H, H-3'), 3.40 (t, J = 9.1 Hz, 1H, H-2'), 3.33 (t,  
J = 8.4 Hz, 1H, H-5'), 3.20 (dd, J = 11.3, 4.8 Hz, 1H, H-3), 2.23–2.15 (m, 3H), 1.92–1.78 (m, 3H), 
1.78–1.69 (m, 2H), 1.68 (s, 3H, H-26), 1.66–1.61 (m, 4H), 1.59 (s, 3H, H-27), 1.55–1.46 (m, 4H), 1.37 
(s, 3H, H-21), 1.32–1.21 (m, 6H), 1.19 (s, 9H, H-3'', H-4'', H-5''), 1.05 (m, 1H, Ha-15), 0.98 (s, 6H,  
H-19, H-28), 0.89 (s, 3H, H-30), 0.87 (s, 3H, H-18), 0.78 (s, 3H, H-29), 0.72 (d, J = 11.3 Hz, 1H, H-5); 
13C-NMR (125 MHz, CDCl3) δ 178.7 (C-1''), 131.6 (C-25), 124.8 (C-24), 96.9 (C-1'), 84.3 (C-20), 
79.0 (C-3), 77.0 (C-3'), 73.7 (C-5'), 73.6 (C-2'), 70.7 (C-12), 70.4 (C-4'), 64.0 (C-6'), 56.0 (C-5), 51.8 
(C-17), 51.5 (C-14), 50.0 (C-9), 48.1 (C-13), 39.9 (C-8), 39.1 (C-1), 39.0 (C-4), 38.9 (C-2''), 37.2  
(C-10), 35.6 (C-22), 34.9 (C-7), 30.8 (C-11), 30.6 (C-15), 28.2 (C-28), 27.5 (C-2), 27.3 (C-3'', C-4'',  
C-5''), 26.8 (C-16), 25.8 (C-26), 22.2 (C-23), 21.5 (C-21), 18.4 (C-6), 17.8 (C-27), 17.1 (C-30), 16.3 
(C-29), 15.9 (C-18), 15.5 (C-19). 
3β,12β,20(S)-trihydroxy-dammar-24-ene 20-O-β-D-glucopyranosyl 6'-benzoyl ester (7C). Colorless oil. 
HRMS (m/z): 749.4591 [M + Na]
+ (calcd. for C43H66O9Na: 749.4605). 
1H-NMR (500 MHz, CDCl3) δ 
8.02 (d, J = 8.4 Hz, 2H, H-3'', H-7''), 7.54 (t, J = 7.4 Hz, 1H, H-5''), 7.41 (t, J = 7.8 Hz, 2H, H-4'',  
H-6''), 5.34 (s, br, 1H), 5.04 (t, J = 6.9 Hz, 1H, H-24), 4.87 (s, br, 1H), 4.67 (d, J = 10.1 Hz, 1H,  
Ha-6'), 4.54 (d, J = 7.7 Hz, 1H, H-1'), 4.46 (dd, J = 11.8, 6.9 Hz, 1H, Hb-6'), 4.23 (s, br, 1H), 3.87 (s, 
br, 1H), 3.64 (m, 1H, H-4'), 3.48 (t, J = 9.2 Hz, 1H, H-3'), 3.37 (t, J = 8.3 Hz, 1H, H-5'), 3.25 (m, 1H, 
H-2'), 3.16 (dd, J = 11.0, 5.0 Hz, 1H, H-3), 2.20–2.15 (m, 3H), 1.93–1.64 (m, 7H), 1.61 (s, 3H, H-26), 
1.59–1.53 (m, 3H), 1.49 (s, 3H, H-27), 1.48–1.33 (m, 4H), 1.31 (s, 3H, H-21), 1.29–1.16 (m, 4H), 1.01 
(m, 1H, Ha-15), 0.95 (s, 6H, H-19, H-28), 0.92 (m, 1H, Ha-1), 0.88 (s, 3H, H-30), 0.85 (s, 3H, H-18), 
0.76 (s, 3H, H-29), 0.69 (d, J = 11.2 Hz, 1H, H-5); 
13C-NMR (125 MHz, CDCl3) δ 166.7 (C-1''), 133.2 
(C-5''), 131.5 (C-25), 130.1 (C-2''), 129.8 (C-3'', C-7''), 128.4 (C-4'', C-6''), 124.8 (C-24), 96.9 (C-1'), 
84.3 (C-20), 79.0 (C-3), 77.2 (C-3'), 73.7 (C-5'), 73.5 (C-2'), 70.8 (C-12), 70.5 (C-4'), 64.4 (C-6'), 56.0 
(C-5), 51.8 (C-17), 51.6 (C-14), 50.0 (C-9), 48.1 (C-13), 39.9 (C-8), 39.1 (C-1), 39.0 (C-4), 37.2 (C-10), 
35.6 (C-22), 34.9 (C-7), 30.8 (C-11), 30.4 (C-15), 28.2 (C-28), 27.5 (C-2), 26.8 (C-16), 25.7 (C-26), 
22.2 (C-23), 21.4 (C-21), 18.4 (C-6), 17.7 (C-27), 17.2 (C-30), 16.2 (C-29), 15.9 (C-18), 15.5 (C-19). 
3.3. Bioassay 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [12] was used to 
test the effect of M1 esters against MGC80-3 cells. MGC80-3 cells (Shanghai Life Academy of Sciences 
Cell Resource Center, Chinese Academy of Sciences, 200 μL) at a density of 5 × 10
3/mL, 1 × 10
4/mL, 
2 × 10
4/mL, 3 × 10
4/mL, 4 × 10
4/mL, 5 × 10
4/mL, respectively, was added into the wells of 96-well Molecules 2013, 18 3700 
 
 
microtiter plates. Each concentration was added to six wells, and three unvaccinated wells were used 
as the control. The plates were put in an incubation box (MCO-18AIC Sanyo Company, Beijing, China) 
with 5% CO2 at 37 °C for 24 h, 48 h and 72 h, respectively. Then, 20 µL of MTT solution (5 μg/mL) 
was added to each well and the plates were incubated for 4 h. 150 µL of DMSO was added to each well 
to dissolve the crystalline. The optical density (OD) values of the clear solutions obtained by centrifuge 
were measured using a microplate reader at 490 nm. The average data of six wells of the same conditions 
are presented as the percentage versus the blank experiment, which represents 100% cell viability. 
4. Conclusions 
In conclusion, we have synthesized a range of monoesters of M1, and identified their structures by 
spectral methods. An acyl group introduced to the 3'-OH, 4'-OH positions of M1 for the first time. 
These esters display anti-tumor activity towards the human gastric cancer cell line MGC80-3 at a 
concentration of 100 μg/mL. 
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